Metreleptin Doesn't Improve Glycemic Control in T1DM

Share this content:
Metreleptin Doesn't Improve Glycemic Control in T1DM
Metreleptin Doesn't Improve Glycemic Control in T1DM

MONDAY, March 6, 2017 (HealthDay News) -- For patients with suboptimally controlled type 1 diabetes mellitus (T1DM), metreleptin does not improve glycemic control, but is associated with reductions in body weight and daily insulin dose, according to a study published online Feb. 21 in Diabetes Care.

Chandna Vasandani, Ph.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues examined the efficacy and safety of metreleptin therapy in five female and three male patients with suboptimally controlled T1DM. Participants received metreleptin subcutaneously twice daily for 20 weeks, followed by four weeks off therapy.

The researchers found that, compared with the baseline value, metreleptin therapy did not lower hemoglobin A1c significantly (mean difference, −0.19 and −0.04 percent, respectively, at 12 and 20 weeks). At weeks 12 and 20 there were significant reductions in mean body weight by 2.6 and 4.7 kg, respectively (P = 0.003), and in daily insulin dose by 12.6 and 15.0 percent, respectively (P = 0.006).

"Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly," the authors write.

One author disclosed financial ties to Amylin and Aegerion. Amylin partially funded the study and Aegerion acquired metreleptin after conclusion of the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

From pre- to post-expansion period, 59 percent relative increase in Medicaid-covered preemptive listings

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

BCG Vaccine Tied to Reduced Hyperglycemia in Type ...

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Many Physicians Not Prepared for End-of-Life Talks With Patients

Many Physicians Not Prepared for End-of-Life Talks With ...

Additional training, reimbursement may foster these critical conversations, authors say

is free, fast, and customized just for you!




Already a member?

Sign In Now »